HOME > ARCHIVE

ARCHIVE

NEW PRODUCTS

December 18, 2006
NEW PRODUCTS

December 18, 2006
REGULATORY NEWS IN BRIEF

December 18, 2006
GSK to Discontinue Research in Japan

December 11, 2006
Blopress Remained Top-selling Drug in 3rd Qtr: IMS Japan

December 11, 2006
Larger Number of Patients per Facility Essential for Spearhead Medical Research: Dr Tanaka

December 11, 2006
BUSINESS NEWS IN BRIEF

December 11, 2006
R&D NEWS IN BRIEF

December 11, 2006
SEMINAR

December 11, 2006
Kenporen Preparing Pamphlet on Generic Drugs

December 11, 2006
GENERIC NEWS IN BRIEF

December 11, 2006
Terumo's Triplex Artificial Blood Vessel Recommended for Approval

December 11, 2006
Criteria Established for "Observation Services"

December 11, 2006
PhRMA

December 11, 2006
NEW PRODUCTS

December 11, 2006
Survey Reveals Major Gap in New Drug Access in US/EU vs. Japan

December 11, 2006
MEDICAL DEVICE NEWS IN BRIEF

December 11, 2006
4 New Drugs Recommended for Approval by 2nd Committee on Drugs

December 11, 2006
NEW PRODUCTS

December 11, 2006
9 New Drugs Recommended for Approval by 1st Committee on Drugs

December 11, 2006

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…